Type I interferon differential therapy for erythroleukemia: Specificity of STAT activation

Blood

Volumn 101, Issue 7, 2003, Pages 2727-2735

  Cull, Vanessa S ^b   Tilbrook, Peta A ^b   Bartlett, Emmalene J ^b   Brekalo, Natalie L ^b   James, Cassandra M ^a  

^a MURDOCH UNIVERSITY   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA INTERFERON 6; ALPHA INTERFERON 9; INTERFERON RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; STAT PROTEIN; UNCLASSIFIED DRUG; DNA; DNA BINDING PROTEIN; INTERFERON; ISOPROTEIN; MILK PROTEIN; STAT1 PROTEIN; STAT1 PROTEIN, MOUSE; STAT3 PROTEIN; STAT3 PROTEIN, MOUSE; STAT5 PROTEIN; TRANSACTIVATOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; ERYTHROLEUKEMIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; CELL CULTURE; CELL DIVISION; DRUG EFFECT; GENE THERAPY; GENETICS; METABOLISM; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SURVIVAL RATE; TREATMENT OUTCOME;

ANIMALS; CELL DIVISION; DNA; DNA-BINDING PROTEINS; GENE THERAPY; INTERFERON TYPE I; LEUKEMIA, ERYTHROBLASTIC, ACUTE; MICE; MILK PROTEINS; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN ISOFORMS; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; STAT5 TRANSCRIPTION FACTOR; SURVIVAL RATE; TRANS-ACTIVATORS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 0038107405     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-05-1521     Document Type: Article

References (98)

1. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukemias: French-American-British (FAB) cooperative group. Br J Haematol. 1976;33:451-458.
2. Klinken SP, Nicola NA, Johnson GR. In vitro-derived leukemic cell lines induced by a raf and myc containing retrovirus differentiates in response to erythropoietin. Proc Natl Acad Sci U S A. 1988;85:8506-8510.
3. Farr TJ, Lai CM, Beilharz MW, et al. A rapid fatal erythroleukemia caused by J2E cells can be treated ex vivo with erythropoietin. Leukemia. 1995;9:900-907.
4. Busfield SJ, Klinken SP. Erythropoietin-induced stimulation of differentiation and proliferation in J2E cells is not mimicked by chemical inductions. Blood. 1992;80:412-419.
5. Tilbrook PA, Bittorf T, Busfield SJ, Chappell D, Klinken SP. Disrupted signalling in a mutant J2E cell line that shows enhanced viability, but does not proliferate or differentiate with erythropoietin. J Biol Chem. 1996;271:3453-3459.
6. Tilbrook PA, Palmer GA, Bittorf T, et al. Maturation of erythroid cells and erythroleukemia development are affected by the kinase activity of Lyn. Cancer Res. 2001;61:2453-2458.
7. Tilbrook PA, Colley SM, McCarthy DJ, Marias R, Klinken SP. Erythropoietin-stimulated Raf-1 tyrosine phosphorylation is associated with the tyrosine kinase Lyn in J2E erythroleukemic cells. Arch Biochem Biophys. 2001;396:128-132.
8. Baron S, Tyring SK, Flesichmann WR, et al. The interferons: mechanisms of action and clinical applications. JAMA 1991;66:1375-1383.
9. Lublin FD, Whitaker JN, Eidelman BH, Miller AE, Arnason BG, Burks JS. Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference. Neurology. 1996;46:12-18.
10. DeWit R, Schattenkerk JK, Boucher CA, Bakker PJ, Veenhof KH, Donner SA. Clinical and virological effect of high dose recombinant interferon alpha in disseminated AIDS-related Kaposis's sarcoma. Lancet. 1988;2:1214-1216.
11. Platanias LC, Golomb HM. Clinical use of interferons: hairy cell, chronic myelogenous and other leukemias. In: Baron S, Coppenhaver FD, Fleishmann WR Jr et al, eds. IFN: Principles and Medical Applications. Galveston, TX: University of Texas Medical Branch at Galveston Press; 1992:487-499.
12. Geng Y, Yu D, Blatt LM, Taylor MW. Gene therapy with an adeno-associated virus carrying an interferon gene results in tumor growth suppression and regression. Cancer Gene Ther. 1996;3:31-38.
13. Santodonato L, Ferrantini M, Gabriele L, et al. Cure of mice with established metastatic friend leukemia cell tumors by a combined therapy with tumor cells expressing both interferon alpha-1 and herpes simplex thymidine kinase followed by ganciclovir. Human Gene Therapy. 1996;7:1-10.
14. Shamseddine A, Taher A, Jaafar H, et al. Interferon alpha is an effective therapy for congenital dyserythropoietic anaemia type I. Eur J Haematol. 2000;65:207-209.
15. Foster GR, Finter NB. Are all type I human interferons equivalent? J Viral Hepatitis. 1998;5:143-152.
16. 19. Gene. 1986;43:111-121.
17. Isaacs A, Lindenmann J. Virus interference, 1: the interferon. Proc R Soc Lond B. 1957;147:258-267.
18. Gresser I. Biological effects of interferons. Soc Invest Dermatol. 1990;95:66-71.
19. Fleischmann CM, Fleishmann WR Jr. Effects of hyperthermia on the in vitro antiproliferative activities of HulFN-α, HulFN-β, and rHulFN-γ employed separately and in combination. J Biol Reg Homeostat Agents. 1988;2:173-185.
20. Barber GN. The interferons and cell death: guardians of the cell or accomplices of apoptosis. Semin Cancer Oncol. 2000;10:103-111.
21. Bartholome EJ, Fabienne W, Crusiaux A, et al. IFNβ interferes with the differentiation of dendritic cells from peripheral blood mononuclear cells: selective inhibition of CD40-dependent IL-12 secretion. J Interferon Cyt Res. 1999;19:471-478.
22. Paquette RL, Hsu NC, Kiertscher SM, et al. IFN-α and GM-CSF differentiate peripheral blood monocytes into potent antigen-presenting cells. J Leukoc Biol. 1998;64:358-367.
23. Luft T, Pang KC, Thomas E, et al. Type I IFNs enhance the terminal differentiation of dendritic cells. J Immunol. 1998;161:1947-1953.
24. Radvanyi LG, Banerjee A, Weir M, Messner H. Low levels of IFN-α induce CD86 (B7.2) expression and accelerates dendritic cell maturation from peripheral blood mononuclear cells. Scand J Immunol. 1999;50:499-509.
25. Biron CA. Interferons α and β as immune regulators - a new look. Immunity. 2001;14:661-664.
26. Tough DF, Borrow P, Sprent J. Induction of bystander T cell proliferation by viruses and type I IFN in vivo. Science. 1996;272:1947-1950.
27. Brinkmann V, Geiger T, Alkan S, Heusser CH. IFN-α increases the frequency of IFN-γ-producing human CD4+ T cells. J Exp Med. 1993;178:1655-1663.
28. Estes DM, Tuo W, Brown WC, Goin J. Effects of type I/type II IFNs and transforming growth factor-β on B-cell differentiation and proliferation: definition of costimulation and cytokine requirements for immunoglobulin synthesis and expression. Immunol. 1998;95:604-611.
29. Lutfalla G, Holland SJ, Cinato E, et al. Mutant U5A cells are complemented by an interferon-alpha beta receptor subunit generated by alternative processing of a new member of a cytokine receptor gene cluster. EMBO J. 1995;14:5100-5108.
30. Uze G, Lutfalla G, Gresser I. Genetic transfer of a functional human interferon alpha receptor into mouse cells: cloning and expression of its cDNA. Cell. 1990;60:225-234.
31. Colamonici O, Yan H, Domanski P, et al. Direct binding to and tyrosine phosphorylation of the alpha subunit of the type I interferon receptor by p135tyk2 tyrosine kinase. Mol Cell Biol. 1994;14:8133-8142.
32. Domanski P, Fish E, Nadeau OW, et al. A region of the beta subunit of the interferon alpha receptor different from box 1 interacts with Jak1 and is sufficient to activate the Jak-STAT pathway and induce an antiviral state. J Biol Chem. 1997;272:26388-26393.
33. Lehtonen A, Matikainen S, Julkunen I. Interferons up-regulate STAT1, STAT2, and IRF family transcription factor gene expression in human peripheral blood mononuclear cells and macrophages. J Immunol. 1997;159:794-803.
34. Cho SS, Bacon CM, Sudarshan C, et al. Activation of STAT4 by IL-12 and IFN-alpha: evidence for the involvement of ligand-induced tyrosine and serine phosphorylation. J Immunol. 1996;157:4781-4789.
35. Fasler-Kan E, Pansky A, Wiederkehr M, Battegay M, Heim MH. Interferon-alpha activates signal transducers and activators of transcription 5 and 6 in Daudi cells. Eur J Biochem. 1998;254:514-519
36. Matikainen S, Sareneva T, Ronni T, Lehtonen A, Koskinen PJ, Julkunen I. Interferon-alpha activates multiple STAT proteins and upregulates proliferation-associated IL-2R alpha, c-myc, and pim-1 genes in human T cells. Blood. 1999;93:1980-1991.
37. Farrar JD, Smith JD, Murphy TL, Leung S, Stark GR, Murphy KM. Selective loss of type I interferon-induced STAT4 activation caused by a minisatellite insertion in Stat2. Nature Immunol. 2000;1:65-69.
38. Krishnan K, Singh B, Krolewski JJ. Identification of amino acid residues critical for the Src-homology 2 domain-dependent docking of STAT2 to the interferon alpha receptor. J Biol Chem. 1998;273:19495-19501.
39. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem. 1998;67:227-264.
40. Darnell JE. STATs and gene regulation. Science. 1997;277:1630-1635.
41. Goh KC, Haque SJ, Williams BR. p38 MAP kinase is required for STAT1 serine phosphorylation and transcriptional activation induced by interferons. EMBO J. 1999;18:5601-5608.
42. Uddin S, Majchrzak B, Woodson J, et al. Activation of the p38 mitogen-activated protein kinase by type I interferons. J Biol Chem. 1999;274:30127-30131.
43. Uddin S, Lekmine F, Sharma N, etal. The Rac1/ p38 mitogen-activated protein kinase pathway is required for interferon alpha-dependent transcriptional activation but not serine phosphorylation of Stat proteins. J Biol Chem. 2000;275:27634-27640.
44. Caraglia M, Abbruzzese A, Leardi A, et al. Interferon-alpha induces apoptosis in human KB cells through a stress-dependent mitogen activated protein kinase pathway that is antagonized by epidermal growth factor. Cell Death Differ. 1999;6:773-780.
45. Arora T, Floyd-Smith G, Espy M.J, Jelinek DF, Dissociation between IFN-alpha-induced antiviral and growth signaling pathways. J Immunol. 1999;162:3289-3297.
46. Swaminathan N, Lai CM, Beilharz MW, Boyer SJ, Klinken SP. Biological activities of recombinant murine interferons alpha 1 and alpha 4: large difference in antiproliferative effect. Antiviral Res. 1992;19:149-159.
47. Lai CM, Swaminathan N, Beilharz MW, Papadimitriou J, Klinken SP. Interferon-alpha inhibits erythropoietin-induced proliferation, but not differentiation, and restricts erythroleukemia development. J Interferon Cytokine Res. 1995;15:669-675.
48. Cooper MC, Levy J, Cantor LN, Marks PA, Rifkind RA. The effect of erythropoietin on colonial growth of erythroid precursors in vitro. Proc Natl Acad Sci U S A. 1974;71:1677-1680.
49. Chappell D, Tilbrook PA, Bittorf T, Colley SM, Meyer GT, Klinken SP. Prevention of apoptosis in J2E erythroid cells by erythropoietin: involvement of JAK2 but not MAP kinases. Cell Death Diff. 1997;4:105-113.
50. Bowtell DD. Rapid isolation of eukaryotic DNA. Anal Biochem. 1987;162:463-465.
51. Cull VS, Bartlett EJ, James CM. Type I interferon gene therapy protects against cytomegalovirus-induced myocarditis. Immunology. 2002;106:428-437.
52. Chen C, Okayama H. High efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol. 1987;7:2745-2752.
53. Lawson CM, Yeow W-S, Lee CM, Beilharz MW. In vivo expression of an interferon alpha gene by intramuscular injection of naked DNA. J Interferon Cytokine Res. 1997;17:255-261.
54. Haq R, Halupa A, Beattie BK, Mason JM, Zanke BW, Barber DL. Regulation of erythropoietin-induced STAT serine phosphorylation by distinct mitogen-activated protein kinases. J Biol Chem. 2002;277:17359-17366.
55. Gregory RC, Jiang N, Todokoro K, Crouse J, Pacifici RE, Wojchowski DM. Erythropoietin receptor and STAT5-specific pathways promote SKT6 cell hemoglobinization. Blood. 1998;92:1104-1118.
56. Socolovsky M, Fallon AE, Wang S, Brugnara C, Lodish H. Fetal anaemia and apoptosis of red cell progenitors in Stat5a-/- 5b-/- mice: a direct role for Stat5 in Bcl-X(L) induction. Cell. 1999;98:181-191.
57. Cull VS, Tilbrook PA, Adenan AS, et al. Dominant action of mutated erythropoietin receptors on differentiation in vitro and erythroleukemia in vivo. Oncogene. 2001;19:953-960.
58. Bartlett EJ, Cull VS, Brekalo NL, Lenzo JC, James CM. Synergy of IFN-A6 and IFN-B DNA immunotherapy for cytomegalovirus infection. Immunol Cell Biol. 2002;80:425-435.
59. Harle P, Cull VS, Agbaga M-P, et al. Differential effect of murine type I IFN transgene in antagonizing HSV-1 replication. J Virol. 2002;66:6558-6567.
60. Harle P, Cull V, Guo L, Papin J, Lawson C, Carr D. Transient transfection of mouse fibroblasts with type I interferon transgenes provides various degrees of protection against herpes simplex virus infection. Antiviral Res. 2002;56:39-49.
61. Borden EC, Lindner D, Dreicer R, Hussein M, Peereboom D. Second-generation interferons for cancer: clinical targets. Semin Cancer Biol. 2000;10:125-144.
62. Geng Y, Yu D, Blatt LM, Taylor MW. Tumor suppressor activity of the human consensus type I interferon gene. Cytokines Mol Ther. 1995;1:289-300.
63. Menike D, Wickramasinghe, SN. Effects of four species of interferon-α on cultured erythroid progenitors from congenital dyserythropoietic anaemia type I. Brit J Haematol. 1998;103:825-830.
64. Busfield SJ, Riches KJ, Sainsbury AJ, Garcia-Webb P, Klinken SP. Retrovirally-produced erythropoietin effectively induces differentiation and proliferation of J2E erythroid cells. Growth Factors. 1993;9:87-97.
65. Callus B, Tilbrook PA, Busfield SJ, Cull VS, Bittorf T, Klinken SP. Amiloride suppresses erythropoietin-induced proliferation and MAP kinase, but potentiates differentiation of J2E cells. Exp Cell Res. 1995;219:39-46.
66. Busfield SJ, Spadaccini A, Riches KJ, Tilbrook PA, Klinken SP. The major erythroid DNA-binding protein GATA-1 is stimulated by erythropoietin but not by chemical inducers of erythroid differentiation. Eur J Biochem. 1995;230:475-480.
67. Choi I, Muta K, Wickrema A, Krantz SB, Nishimura J, Nawata H. Interferon gamma delays apoptosis of mature erythroid progenitor cells in the absence of erythropoietin. Blood. 2000;95:3742-3749.
68. Anderson CC, Matzinger P. Danger: the view from the bottom of the cliff. Sem Immunol. 2000;12:231-238.
69. Tarumi T, Sawada K, Sato N, et al. Interferon-alpha-induced apoptosis in human erythroid progenitor cells. Exp Hematol. 1985;23:1310-1318.
70. Roos G, Leanderson T, Lundgren E. Interferon-induced cell cycle changes in human hematopoietic cell lines and fresh leukemic cells. Cancer Res. 1984;44:2358-2362.
71. Sangfelt O, Erickson S, Castro J, Heiden T, Einhorn S, Grander D. Induction of apoptosis and inhibition of cell growth are independent responses to interferon-alpha in hematopoietic cell lines. Cell Growth Differ. 1997;8:343-352.
72. Grumbach IM, Fish EN, Uddin S, et al. Activation of the Jak-STAT pathway in cells that exhibit selective sensitivity to the antiviral effects of IFN-beta compared with IFN-alpha. J Interferon Cytokine Res. 1999;19:797-801.
73. Fish EN, Uddin S, Korkmaz M, Majchrzak B, Druker BJ, Platanias LC. Activation of a CrkL-STAT5 signaling complex by type I interferons. J Biol Chem. 1999;274:571-573.
74. Stancato LF, Sakatsume M, David M, et al, Beta interferon and oncostatin M activate Raf-1 and mitogen-activated protein kinase through a JAK1-dependent pathway. Mol Cell Biol. 1997;17:3833-3840.
75. Berger LC, Tamir A, Ben-David Y, Hawley RG. Dose-dependent activation of p21 ras by IFN-beta. J Interferon Cytokine Res. 1997;17:757-762.
76. Burfoot MS, Rogers NC, Watling D, et al. Janus kinase-dependent activation of insulin receptor substrate 1 in response to IL-4, oncostatin M, and the interferons. J Biol Chem. 1997;272:24183-24190.
77. Rani MR, Leaman DW, Han Y, et al. Catalytically active TYK2 is essential for interferon-beta-mediated phosphorylation of STAT3 and interferon-alpha receptor-1 (IFNAR-1) but not for activation of phosphoinositol 3-kinase. J Biol Chem. 1999;274:32507-32511.
78. Lutfalla G, Holland SJ, Cinato E, et al. Mutant U5A cells are complemented by an interferon-alpha beta receptor subunit generated by alternative processing of a new member of a cytokine receptor gene cluster. EMBO J. 1995;14:5100-5108.
79. Platanias LC, Uddin S, Domanski P, Colamonici OR. Differences in interferon alpha and beta signaling: interferon beta selectively induces the interaction of the alpha and betaL subunits of the type I interferon receptor. J Biol Chem. 1996;271:23630-23633.
80. David M, Chen HE, Goelz S, Larner AC, Neel BG. Differential regulation of the alpha/beta interferon-stimulated Jak/STAT pathway by the SH2 domain-containing tyrosine phosphatase SHPTP1. Mol Cell Biol. 1995;15:7050-7058.
81. Hilkens CMU, Schlaak JF, Kerr IM. Molecular analysis of responses to interferon-alpha subtypes in human T cells and dendritic cells. J Interferon Cytokine Res. 2002;22(suppl 1):S56.
82. Cutrone EC, Langer JA. Contributions of cloned type I interferon receptor subunits to differential ligand binding. FEBS Lett. 1997;404:197-202.
83. Lewerenz M, Mogensen KE, Uze G. Shared receptor components but distinct complexes for α and β-interferons. J Mol Biol. 1998;282:585-599.
84. Chunthrapai A, Gibbs V, Lu J, et al. Determination of residues involved in ligand binding and signal transmission in human IFN-α receptor 2. J Immunol. 1999;163:766-773.
85. Williams BR. Signal integration via PKR. Sci STKE. 2001;89:RE2. Review.
86. Kuhen KL, Samuel CE. Mechanisms of interferon action: functional characterization of positive and negative regulatory domains that modulate transcriptional activation of the human RNA-dependent protein kinase Pkr promoter. Virology. 1999;254:182-195.
87. Landolfo S, Gribaudo G, Angeretti A, Gariglio M. Mechanisms of viral inhibition by interferons. Pharmacol Therapeutics. 1995;65:415-442.
88. Meurs E, Chong K, Galabru J, et al. Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon. Cell. 1990;62:379-390.
89. Kumar A, Yang YL, Flati V, et al. Deficient cytokine signaling in mouse embryo fibroblasts with a targeted deletion in the PKR gene: role of IRF-1 and NF-kappaB. EMBO J. 1997;16:406-416.
90. Wong LH, Krauer KG, Hatzinisiriou I, et al. Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma. J Biol Chem. 1997;272:28779-28785.
91. Raveh T, Hovanessian AG, Meurs EF, Sonenberg N, Kimchi A. Double-stranded RNA-dependent protein kinase mediates c-Myc suppression induced by type I interferons. J Biol Chem. 1996;271:25479-25484.
92. Salzberg S, Heller A, Zou JP, Collart FR, Huberman E. Interferon-independent activation of (2′-5′) oligoadenylate synthetase in Friend erythroleukemia cell variants exposed to HMBA. J Cell Sci. 1996;109:1517-1526.
93. Cull VS, Broomfield S, Bartlett EJ, Brekalo NL, James CM. Coimmunisation with type I IFN genes enhances protective immunity against cytomegalovirus and myocarditis in gB DNA-vaccinated mice. Gene Therapy. 2002;9:1369-1378.
94. Li S, Xia X, Zhang X, Suen J. Regression of tumours by IFN-alpha electroporation gene therapy and analysis of the responsible genes by cDNA array. Gene Therapy. 2002;9:390-397.
95. Hiroishi K, Tuting T, Lotze MT. IFN-alpha-expressing tumor cells enhance generation and promote survival of tumor-specific CTLs. J Immunol. 2000;164:567-572.
96. Currier NL, Miller SC. Influence of an interferon inducer on bone marrow transplant reconstitution in irradiated, leukemic mice: elevated natural killer cell numbers and improved life span. Nat Immunol. 1998;16:6-17.
97. Gresser I, Belardelli F. Endogenous type I interferons as a defence against tumours. Cytokine Growth Factor Rev. 2002;13:111-118.
98. Piehler J, Rosiman LC, Shreiber G. New structural and functional aspects of the type I interferon-receptor interaction revealed by comprehensive mutational analysis of the binding interface. J Biol Chem. 2000;275:40425-40433.